Prostate Cancer Treatment to Revolutionize Standard of Care and Multiple Treatment Options

Prostate cancer is among serious health issue among men has large socioeconomic impact on the society. It is the most common cancer diagnosed among men in developed regions, while it is sixth most common cancer diagnosed in less developed nations. Routine screening, early diagnosis, and recent treatment options have enabled increased survival of prostate cancer patients. Prostate cancer is an abnormal and uncontrolled growth of cells in prostate gland of a male individual. Approximately 75% of prostate cancers are developed sporadically in which genetic changes occur after birth. Although, cause prostate cancer is largely unknown, some of the prime factors associated with the disease include obesity, overweight and past history of certain cancers. A person with cardiovascular disease is more prone to advanced metastatic cancer.

Androgens have significant role in the pathogenesis of prostate cancer and therefore androgen-deprivation therapy (ADT) was found to be most useful in treating of locally advanced or metastatic prostate cancer. Presently, the prostate cancer therapeutics market is driven by major drugs such as Zytiga (Johnson & Johnson), Xtandi (Astellas Pharma, Inc. / Medivation, Inc.), Provenge (Dendreon Corporation), Jevtana (Sanofi) and Xofigo (Bayer Healthcare Pharmaceutical, Inc.). The prostate cancer therapeutics market is slated to increasing rapidly in the near future owing to promising drugs in the pipeline. These drugs are expected to drive the market during the forecast period from 2015 to 2023. In 2013, Johnson & Johnson acquired Aragon Pharmaceuticals that has second generation androgen receptor signaling inhibitor (ARN-509), a highly potential drug for treatment of castration resistant prostate cancer. This acquisition is seen as a strategic move by Johnson & Johnson to mitigate the expected slowing of Zytiga sales.

Download Free exclusive Sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6562

Zytiga, launched in 2011, clocked sales of over USD 1 billion in 2012 and works by targeting the enzyme CYP17A1 responsible for androgen production. The drug is expected to lose its patent protection in 2016. Moreover, Zytiga is facing stiff competition from Xtandi (Astellas Pharma, Inc. / Medivation, Inc.). The Astellas’ drug has already matched the sales of Zytiga and is rapidly moving further upstream as the patients are using treatment for long period and urologists continuing to adopt the drug. High prices of newer drugs and uncertain reimbursement policies will be restraining the market to some extent. However, the growing awareness about prostate cancer, rapid urbanization, and government efforts to fund cancer treatment will drive the market during the forecast period from 2015 to 2023.

On the basis of geography, the global prostate cancer therapeutics market can be segmented into four major regions, namely, North America, Europe, Asia Pacific, and Rest of the world. American men have highest rates of prostate cancer followed the European males. It is estimated that more than 230,000 new cases of prostate cancer were diagnosed in the U.S. in 2014. In U.K., more than 40,000 new cases are registered having prostate cancer, and about 11,000 deaths occur annually. Therefore, the global prostate cancer therapeutics market has been traditionally dominated by North America Asia region ranks lowest in terms of rate of prostate cancer.

Some of the key players in this market are Johnson & Johnson, AstraZeneca plc, Astellas Pharma, Inc., Sanofi, Medivation, Inc., Ipsen SA and Bayer Healthcare Pharmaceutical, Inc.

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

90 State Street, Suite 700 Albany, NY 12207

This release was published on openPR.